CIK 0001427925
- Non-accelerated filer
- Smaller reporting company
TALPHERA, INC.
Sign in to watch- Ticker
- TLPH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 412193603
- Phone
- +1 650-216-3500
- Business address
- 1850 GATEWAY DRIVE, SUITE 175, SAN MATEO, CA, 94404
- Former names
- ACELRX PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-12-14 | Angotti Vincent J. Chief Executive Officer | Purchase | +3,610 | $2.78 | $10K | 54,650 |
| 2018-12-14 | ASADORIAN RAFFI Chief Financial Officer | Purchase | +5,000 | $2.78 | $14K | 52,000 |
| 2018-12-12 | Angotti Vincent J. Chief Executive Officer | Purchase | +10,000 | $2.99 | $30K | 51,040 |
| 2018-11-19 | Palmer Pamela P Chief Medical Officer | Purchase | +16,000 | $3.07 | $49K | 472,134 |
| 2018-11-15 | EDWARDS MARK G Director | Purchase | +20,700 | $2.82 | $58K | 181,000 |
| 2018-11-13 | ASADORIAN RAFFI Chief Financial Officer | Purchase | +5,000 | $3.13 | $16K | 47,000 |
| 2018-11-02 | Hamel Lawrence G Chief Development Officer | Grant or award | +5,000 | $2.23 | $11K | 34,795 |
| 2018-11-02 | Hamel Lawrence G Chief Development Officer | Returned to the company | −5,000 | $5.00 | $25K | 29,795 |
| 2018-11-02 | Hamel Lawrence G Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +26,125 | 26,125 | ||
| 2018-11-02 | Hamel Lawrence G Chief Development Officer | Returned to the company · Stock Option (Right to Buy) | −5,000 | 21,125 | ||
| 2018-11-02 | Dasu Badri N Chief Engineering Officer | Grant or award · Stock Option (Right to Buy) | +31,625 | 31,625 | ||
| 2018-11-02 | ASADORIAN RAFFI Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +40,562 | 40,562 | ||
| 2018-11-02 | Palmer Pamela P Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +47,575 | 47,575 | ||
| 2018-11-02 | Angotti Vincent J. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +96,250 | 96,250 | ||
| 2018-10-15 | Hamel Lawrence G Chief Development Officer | Sale | −5,216 | $5.00 | $26K | 29,795 |
| 2018-10-15 | Dasu Badri N Chief Engineering Officer | Sale | −28,351 | $5.00 | $142K | 54,061 |
| 2018-09-24 | Hamel Lawrence G Chief Development Officer | Sale | −6,953 | $4.50 | $31K | 35,011 |
| 2018-08-31 | Dasu Badri N Chief Engineering Officer | Grant or award | +8,022 | $1.49 | $12K | 82,412 |
| 2018-08-31 | ASADORIAN RAFFI Chief Financial Officer | Grant or award | +10,000 | $1.49 | $15K | 42,000 |
| 2018-08-31 | Angotti Vincent J. Chief Executive Officer | Grant or award | +6,040 | $1.49 | $9K | 41,040 |
Page 16 of 17 · 329 trades